Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

- Building on Phase III registration trial of VELCADE and rituximab, Millennium initiates new clinical trial with novel combination of VELCADE with bendamustine and rituximab to further advance treatment of patients

with follicular lymphoma -

CAMBRIDGE, Mass., Feb. 20 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the initiation of a multi-center, Phase II trial to evaluate VELCADE in combination with emerging agent, bendamustine, and current standard of care, rituximab, in patients with relapsed follicular lymphoma, a subset of non-Hodgkin's lymphoma (NHL). This trial is part of the Company's comprehensive development program in NHL, which represents a significant growth opportunity for VELCADE.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"We designed this trial to combine three active agents in NHL with the goal of enhancing the clinical outcomes of this patient population," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "We are hopeful this novel combination will add to the growing body of data that show the potential of VELCADE to be part of the standard of care in follicular lymphoma, similar to what we've seen in multiple myeloma."

The primary endpoint of the open-label trial is complete remission with secondary endpoints including progression free survival and duration of remission. The trial is expected to enroll approximately 75 patients.

In previous studies, VELCADE as a single-agent and as part of combination therapy has shown promising remission rates and time-to-disease progression in patients with NHL. Th
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
...  The Centers for Disease Control and Prevention (CDC) has ... as many people as car accidents.  Drug diversion is ... as the U.S. House of Representatives Energy and Commerce ... – "Prescription Drug Diversion: Combating the Scourge" ...
... SYDNEY, March 1, 2012  In a single bound, Nepean ... radiation therapy for its prostate cancer cases to a ... Arc Therapy), a technique that is even quicker with ... NCCC physicians treated their first patient with prostate cancer ...
Cached Medicine Technology:Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 2Australian Clinic Puts Prostate Cancer Radiation Therapy on Fast Track With Elekta VMAT and Integrity Digital Control System 3
(Date:4/23/2014)... MD (April 23, 2014) The American Gastroenterological ... the 2014 AGA Research Scholars. The AGA Research ... investigators to develop independent and productive research careers ... Scholar Awards fund an additional year allowing for ... committed to supporting junior faculty who are paving ...
(Date:4/23/2014)... scientists led by a researcher from the Cancer Science ... of Singapore has identified the cancer specific stem cell ... possibility of developing new drugs for the treatment of ... research group, led by Dr Chan Shing Leng, Research ... time that a cancer-specific variant of a cell surface ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
Breaking Medicine News(10 mins):Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... by the Seychelles Food and Agriculture Organization (FAO) to ... all the necessary help like donating equipment such as ... Department of Natural resources. This done as they would ... local outbreak. The FAO’s country correspondent, Antoine Marie Moustache ...
... problems of health capturing people worldwide it is very important to ... it is done at the workplace for people who work- almost ... educate the employees on how to attain a better health and ... stay fit and not turn obese. This also helps to cut ...
... MCD today said there was a rise in the breeding ... //a special drive to check breeding of the vector. ... for the spread of the dreaded fever, has been reported ... the Corporation said in a release. ,The MCD ...
... has urged the doctors working in various hospitals in ... vaccine, as recommended by World Health Organisation //. ... intra-dermal route, the doctors could vaccinate five patients from ... per cent less as compared to intra-muscular vaccine. ...
... who stutter, cope with their stressors and emotions as ... with the speech difficulty //. , ,"Our ... apt to be emotionally aroused, less able to settle ... attention and emotion during everyday stressful or challenging situations," ...
... postmortem brain tissue from patients with schizophrenia, researchers at ... with scientists at the City University of New York, ... high level of erbB4 receptor activity and reduced NMDA ... prefrontal cortex of schizophrenic patient were stimulated. Thus found ...
Cached Medicine News:Health News:An analysis of pros and cons of health education at the workplace 2Health News:Supporting children with stress key to improve stuttering 2Health News:Supporting children with stress key to improve stuttering 3Health News:Schizophrenia Complicates With Altered Receptor Activity 2Health News:Schizophrenia Complicates With Altered Receptor Activity 3
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
The link classic plus hip stem for cemented primary hip replacement surgery...
The uncemented hip joint prosthesis system...
The Quatroloc primary hip system offers 35 primary stems to fit almost all femurs for primary hip arthroplasty....
Medicine Products: